KRYS · Krystal Biotech Inc
Price
Snapshot
50 fields · last close| Market Cap | $9.48B |
| P/E | 39.15 |
| Float | 25.88M |
| Beta | 0.64 |
| Volatility | 16.1% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 74.9 |
| Price | 311.62 |
| Change | −2.66% |
| Prev Close | 320.13 |
| Open | 320.44 |
| Day Low | 317.05 |
| Day High | 328.48 |
| Avg Vol | 0 |
| Avg $ Vol | $82.64M |
| 52W High | 382.54 |
| 52W Low | 183.03 |
| 52W Pos | 64.5% |
| From High | −18.54% |
| From Low | +70.26% |
| Max DD 1Y | −17.34% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −5.02% |
| SMA 50 | −8.12% |
| SMA 200 | +1.51% |
| RSI (14) | 42.5 |
| Vol 30D | 31.8% |
| Vol 90D | 40.4% |
| 1Y Range | 183–383 |
| Daily bars | 540 |
| Perf Week | −2.99% |
| Perf Month | −6.33% |
| Perf Quarter | −4.49% |
| Perf Half Y | +19.43% |
| Perf Year | +67.80% |
| Perf YTD | +26.21% |
| Prev Day | −2.66% |
| Clavix | B |
| Debt / Eq | 0.00 |
| Curr Ratio | 9.95 |
| Int Cover | -9.8× |
| FCF Margin | 48.5% |
| Rev Growth | +33.9% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 14 / 35 |
Clavix risk grade
regraded every trading dayKRYS grades B, 74.9 of 100. Steadiest on News Sentiment (67), most exposed on Price Stability (58, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 14 of 35 in Biotechnology by Clavix score.
How rough the ride is
| KRYS | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.64 | 0.50 |
| Volatilityannualized | 16.1% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | −17.3% | — |
| Typical daily movemedian absolute daily change | 1.39% | — |
| Days beyond ±3%of the last 252 sessions | 45 (18%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| KRYS | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.64 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| KRYS | |
|---|---|
| 1 week | −3.0% |
| 1 month | −6.3% |
| Year to date | +26.2% |
| 1 year | +67.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| KRYS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 30 Jul |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 26 · 3 |
| Directionarticles whose tone is improving vs worsening | 26 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| KRYS | |
|---|---|
| Revenue growthyear over year | +33.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openKrystal Biotech reported early results for its drug KB113 in a study of patients with Gorlin syndrome, a rare genetic condition. More than 80% of the lesions assessed shrank after treatment.
Krystal Biotech (KRYS) reported early results for its drug KB113 in a small study of patients with Gorlin syndrome, a rare inherited condition that causes repeated skin tumors. More than 80% of the tumors measured in the study shrank during treatment.
HC Wainwright reissued a buy rating on Krystal Biotech stock and set a $361.00 price target. The brief article provides no other company-specific information.
Krystal Biotech reported early results from a small pilot study of KB113, an experimental treatment injected directly into tumors to help the immune system fight them, showing that more than 80% of assessed skin cancer lesions shrank in patients with Gorlin syndrome (a rare genetic condition that causes many basal cell skin cancers). The company has also started talks with the FDA about the program.
Krystal Biotech disclosed clinical data from a small pilot study of its experimental drug KB113, which is being tested as a treatment for basal cell skin cancers in patients with Gorlin syndrome (a rare condition that causes recurring skin tumors). A study investigator is presenting the results as a poster at a pediatric dermatology research conference in Alexandria, Virginia.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | B | $9.03B | 109.13 | 1.19 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.96B | 86.95 | 0.40 | Compare |
| TWST | Twist Bioscience Corp | D | $8.92B | — | 2.16 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| CYTK | Cytokinetics Inc | B+ | $8.67B | — | 0.42 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $10.47B | — | -1.09 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $8.24B | — | 1.34 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.14B | 18.45 | 1.82 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.